Back to Search
Start Over
DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE
- Source :
- Journal of Neurology, Neurosurgery & Psychiatry. 87:e1.47-e1
- Publication Year :
- 2016
- Publisher :
- BMJ, 2016.
-
Abstract
- Background As disease-activity-free status is now a viable treatment goal in relapsing multiple sclerosis (RMS), no evidence of disease activity (NEDA) is gaining increasing acceptance as an outcome measure. Objective To determine the percentage of RMS patients who achieved NEDA in the DECIDE study. Methods DECIDE was a phase 3 study of 150 mg subcutaneous daclizumab high-yield process (DAC HYP) every 4 weeks versus weekly 30 mcg intramuscular (IM) interferon (IFN) beta-1a over 96–144 weeks. NEDA was defined as no relapses, no 12-week confirmed disability progression, no new/enlarging T2 (NET2) lesions, and no gadolinium-enhancing (Gd+) lesions. Results A greater percentage of patients receiving DAC HYP than IFN beta-1a achieved NEDA by week 96 (24.3% [198/816] vs 13.9% [116/834]; odds ratio [OR]: 1.983 [95% confidence interval (CI): 1.540–2.554]; P Conclusions A significantly greater percentage of patients treated with DAC HYP than with IM IFN beta-1a achieved NEDA. Sponsors: Biogen, AbbVie Biotherapeutics.
- Subjects :
- medicine.medical_specialty
Daclizumab HYP
business.industry
Multiple sclerosis
Interferon beta-1a
Phases of clinical research
Odds ratio
Treatment goals
medicine.disease
Gastroenterology
Confidence interval
Surgery
Psychiatry and Mental health
Daclizumab
Internal medicine
medicine
Neurology (clinical)
business
medicine.drug
Subjects
Details
- ISSN :
- 1468330X and 00223050
- Volume :
- 87
- Database :
- OpenAIRE
- Journal :
- Journal of Neurology, Neurosurgery & Psychiatry
- Accession number :
- edsair.doi...........f783a665842f10370a707e4e7826126d